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A B S T R A C T Human growth hormone (hGH) is
known to be a potent stimulator of somatomedin
secretion in vivo. The induction of somatomedin by
growth hormone has been difficult to study in vitro,
however, because no organ containing a high con-
centration of sQmatomedin has been identified. Be-
cause fetal mouse explants have been shown to produce
somatomedin in vitro, we have undertaken studies
to determine whether postnatal human fibroblast
monolayers also produce somatomedin, and if so,
whether its production is regulated by other hormones.
Quiescent human fibroblasts were exposed to serum-
free minimum essential medium, and the medium
was assayed for somatomedin concentration using a
specific radioimmunoassay for somatomedin-C. A
progressive rise in immunoreactive somatomedin to
0.08 U/ml per 105 cells per 24 h was observed over 72 h
of incubation. This was an underestimation of the
actual concentration of immunoreactive somatomedin
since the amount measured following acid treatment
was at least fourfold higher than in the untreated
medium. Growth hormone stimulated immunoreactive
somatomedin production in a dose-dependent manner:
5 ng hGH/ml = 0.1 U/ml per 105 cells; 50 ng hGH/ml
= 0.25 U/ml per 105 cells. Platelet-derived growth
factor and fibroblast growth factor were also stimu-
latory, but epidermal growth factor, thyroxine, or corti-
sol had no effect. Media that had been exposed to
human fibroblasts stimulated DNA synthesis in
BALB/c 3T3 fibroblasts (a cell type that does not
produce somatomedin). Medium-derived immuno-
reactive somatomedin eluted from Sephacryl S-200
in two major peaks (150,000 and 8,000 mol wt).
The higher molecular weight peak is similar to the
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one observed when whole serum was used. These
studies provide a model system for studying the
humoral and nonhumoral factors that control the bio-
synthesis of somatomedin by human tissues. Since
immunoreactive somatomedin production may be a
rate-limiting factor for fibroblast growth, the delinea-
tion of the hormonal control of somatomedin produc-
tion should lead to a better understanding of the
mechanisms controlling human fibroblast growth.
INTRODUCTION
The somatomedins, a family of growth hormone-
dependent, insulinlike peptide growth factors, have
been shown to be mitogenic for a variety of types of
cultured cells (1-6). Cartilage from various species and
fibroblasts derived from chick (7) and mouse (8)
embryos fail to synthesize DNA or undergo mitosis
normally when incubated in somatomedin-deficient
serum. Evidence has been published, however, that
hypopituitary serum is as effective as normal serum in
increasing thymidine incorporation (7) and mitosis (9)
by cultured human fibroblasts. Although such variables
as species of cell origin (7), culture conditions (10), or
differences in the methods by which the serum is
prepared (11) might account partially for these
differences in somatomedin dependancy, other ex-
planations must be considered. For example, the effect
of reducing the somatomedin concentration may be
masked by a synergism between the small amounts of
residual somatomedin remaining in hypopituitary
serum and peptides that are not growth-hormone
dependent, such as platelet-derived growth factor
(PDGF)1 (12). Alternatively, it is possible that the effect
of somatomedin deficiency in serum is masked by the
IAbbreviations used in this paper: BSA, bovine serum
albumin; DME, Dulbecco's modified minimum essential
medium; FCS, fetal calfserum; hGH, human growth hormone;
MEM, minimum essential medium; PDGF, platelet-derived
growth factor; PPP, platelet-poor plasma; RIA, radio-
immunoassay.
J. Clin. Invest. C The American Society for Clinical Investigation, Inc. - 0021-9738/81/0110010110 $1.00
Volume 67 January 1981 10-19
somatomedin production of the cultured cells them-
selves. Indeed, there are reports of production and
release of growth factors into medium of cultured
transformed cells (13-15) and cells that proliferate in
very low serum concentrations (16). Explants of fetal
mouse and rat liver (17, 18) and a number of other fetal
mouse tissues are able to secrete immunoreactive
somatomedin into the culture medium. Atkison et al.
(19) have reported recently that monolayer cultures of
human embryonic lung fibroblasts likewise release
immunoreactive somatomedin. Because immunoreac-
tive somatomedin production might be a rate-limiting
step for human fibroblast replication, we have assessed
the capacity of cultured postnatal human fibroblasts to
produce immunoreactive somatomedin. We have also
observed the effects of human growth hormone and
other mitogens contained in serum on immunoreactive
somatomedin production.
METHODS
Human fibroblasts were purchased from the Human Mutant
Genetic Cell Repository, Camden, N. J. Dermal fibroblasts
(strain 498) from a normal 3-yr-old donor were used in these
studies. BALB/c 3T3 fibroblasts were a gift of Dr. Charles
Stiles. Dulbecco's modified minimum essential medium
(DME) was purchased from Flow Laboratories, Inc., Rock-
ville, Md. Eagle's minimum essential medium (MEM), fetal
calf serum, penicillin, and streptomycin were purchased
from GIBCO, Grand Island Biological Co., Grand Island,
N. Y. All cultures were plated in plastic petri dishes (Falconi
Labware, Div. Becton, Dickinson & Co., Oxnard, Calif.).
Bovine serum albumin (Sigma Chemical Co., St. Louis, Mo.,
fraction V) was determined to be free of immunoreactive
somatomedin-C when assayed at a concentration of 50 mg/ml.
[methyl-3H]Thymidine (6 Ci/mM) was purchased from New
England Nuclear, Boston, Mass. Porcine insulin (PJ 5682)
was a gift from Eli Lilly Company, Indianapolis, Ind. Immuno-
chemical grade human growth hormone (hGH) (HS 1144)
and bovine growth hormone (B-16) were obtained from the
National Pituitary Agency, Baltimore, Md. The human
hormone preparation has 0.97 U hGH/mg, <1% contamina-
tion by other proteins, and is free of fibroblast growth-factor-
like biological activity (8). The somatomedin-C used in these
studies was purified to homogeneity as determined by
multiple criteria (20). Mouse epidermal growth factor and
bovine fibroblast growth factor were purchased from
Collaborative Research Inc., Waltham, Mass., and the
manufacturer stated that they were >99% pure. PDGF was
prepared by the following method: outdated human plate-
lets were washed in 17 mM Tris HCI, pH 7.5, and concentrated
by centrifugation. The platelet pellet was freeze-thawed,
then boiled for 10 min. The boiled extract was centrifuged
at 3,000 g for 30 min to remove particulate debris. The
supematant fluid was further purified using CM Sephadex
chromatography, Pharmacia Fine Chemicals, Piscataway,
N. J. (21). PDGF prepared in this manner is purified 250-
fold over crude platelet homogenate and contains no somato-
medin-C by radioimmunoassay. Human platelet poor plasma
(PPP) was prepared by placing freshly drawn blood in pre-
chilled plastic centrifuge tubes without anticoagulant and
immediately centrifuging at 5,000 g. After removing the
supematant fluid and repeating the centrifugation at 10,000 g
for 30 min, the supemate was heated to 56C 'for 30 min and
centrifuged at 5,000 g for 20 min. The resulting supematant
fluid was dialyzed against 0.15 M sodium chloride and stored
at -20°C until used. PPP prepared by this method is free of
PDGF-like biological activity (12). Hypopituitary PPP was
obtained from two hypopituitary donors who were markedly
deficient in immunoreactive somatomedin-C (<4 ng/ml), and
was prepared in the same way as normal PPP.
Cell culture techniques. Cells were cultured in 10-cm
dishes (Falcon 3001) in MEM containing 10% fetal calf
serum (FCS) and were maintained in a humidified incubator
containing 5% CO2. The medium was changed every 3rd d
and the cells were harvested by trypsinization and replated
once weekly (split ratio, 1:4). Both stock and test cultures
were tested for mycoplasma contamination (22) and were
found uncontaminated. To assess immunoreactive soma-
tomedin production, fibroblasts (between the 8th and 12th
passage) were plated in 1.5-cm wells (Falcon 3008) at a
density of 5,000 cells/cm2 in MEM containing 10% FCS,
penicillin (100 U/ml), and streptomycin (100 ;tg/ml). This
medium was changed every 3 d until the cells reached
confluency. 3 d after the last medium change, confluent
monolayers were washed three times with serum-free MEM
and incubated with 0.5 ml serum-free MEM containing 0.1%
bovine serum albumin (BSA).2 The media were sampled at
the times indicated in the Results section, either by removing
of an aliquot and replacing it with an equal volume of MEM-
0.1% BSA, or by removing the entire 0.5-ml incubation
volume. Samples were immediately centrifuged at 1,400 g for
10 min to remove particulate debris and the supematant
fluids were stored at -20'C until they were assayed for
somatomedin content. Growth hormone and other mitogens
were tested at various concentrations by adding the hormone
(in MEM-0.1% BSA) to fibroblast monolayers that had been
washed free of serum-containing medium. Samples were then
processed and collected in the manner described above. At
each time point, duplicate monolayers were washed twice,
the cells were removed by trypsinization, and a 0.5-ml
aliquot was placed in 9.5 ml of 0.15 M NaCl. Each sample
was counted three times in a particle data counter (Coulter
Electronics, Inc., Hialeah, Fla.) and the mean of six deter-
minations was used as the cell number per monolayer.
Quantitation of immunoreactive somatomedin in culture
media. The preparation of somatomedin-C used for iodina-
tion had a specific activity of 10,142 U/mg protein.3 It was
iodinated with sodium 1251 (Amersham-Searle, Chicago, Ill.)
by a chloramine T method (23). Specific activities varied from
190-350 ,uCi/,ug. The iodinated hormone was purified by af-
finity chromatography using the IgG fraction of a rabbit
anti-human somatomedin-C antibody coupled to Sephrose
4B (Pharmacia). The radioimmunoassay used rabbit anti-
human somatomedin-C antibody in a final dilution of 1:12,000
(24). This assay is highly specific for somatomedin-C and
insulinlike growth factor I, which produce identical curves of
competition (25). Insulinlike growth factor II, somatomedin-
A, or multiplication-stimulating activity 111-2 have potencies
of 2.4, 5, and 1.2%, respectively. The immunoassay reference
standard is an aliquot of the somatomedin preparation used
for iodination that has been judged by multiple criteria to
have a purity not <90% (20).
In addition to measurement of immunoreactive soma-
2 Cells that were incubated in serum-free medium were
91% viable by trypan-blue exclusion. In addition, the de-
tachment rate during this period was determined by cell
counting to be <5%.
31 U is defined as the quantity of somatomedin contained
in a pool of normal reference serum and is equivalent to 45 ng
of the pure peptide.
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tomedin in unextracted fibroblast culture media, media were
assayed after treatment with acid. In the acid treatment,
1.0 ml of the medium sample was incubated with 1.0 ml of
2 M acetic acid at 37°C for 30 min. The pH of the incuba-
tion mixture was 3.6. The acidified sample was then lyophi-
lized to dryness and reconstituted in 0.03 M phosphate
buffer, pH 7.5. The immunoreactive somatomedin content
of both native and acid-treated media is expressed as U/ml
per 105 cells.
Medium samples that had been acidified and neutralized
were tested for their ability to compete with 125I-somatomedin-
C for binding to placental membranes. Medium aliquots of
5-200 pl, '25I-somatomedin-C (20,000 cpm)/tube, and
200 ,ug placental membrane protein were incubated in Tris
0.05 M, pH 7.4, for 16 h. After this incubation the membranes
were washed, and the bound radioactivity was detemined.
The standard for this assay was a partially purified prepara-
tion of somatomedin-C which had been calibrated in the
radioimmunoassay (RIA) against pure somatomedin-C.
Measurement of bioactive somatomedin in culture media.
BALB/c 3T3 fibroblasts, which do not produce immuno-
reactive somatomedin, were plated at d-1,000 cells/microtest
well in DME containing 10% FCS, penicillin (100 U/ml),
and streptomycin (100 i&g/ml). Confluent monolayers were
washed twice with serum-free DME and exposed for 5 h to
DME containing partially purified PDGF (500 ng/well). This
medium was removed and replaced with DME containing
5% hypopituitary PPP and either pure somatomedin-C
(1-7 ng/ml) or conditioned MEM (10-60% of final volume).
After 48 h incubation, DNA synthesis was measured by a
previously described autoradiographic method (26).
Characterization of immunoreactive somatomedin in
media. 20 ml of medium that had been exposed to fibro-
blast monolayers for 48 h were dialyzed (Spectopor 3, mol
wt cut off 3,500) against 1 liter of 0.025 M phosphate buffer,
pH 7.4, for 48 h with four changes of buffer. The retained
material was lyophilized to dryness, reconstituted with 1.0 ml
water, applied to a 1.6 x 80-cm Sephacryl S-200 column,
and eluted with 0.05 M phosphate buffer, pH 7.4. Each
fraction was acidified for 30 min (pH adjusted to 3.6), lyophi-
lized to dryness, reconstituted in 0.03 M phosphate buffer
(pH 7.4), and assayed for immunoreactive somatomedin
content. An additional 10-ml aliquot of medium was acidified
with an equal volume of 2.0 M acetic acid, final pH 3.6, and
lyophilized to dryness. The material was reconstituted in
0.5 ml acetic acid containing 10,000 cpm l5I-somatomedin-C,
applied to a 1.6 x 20-cm Sephadex G-50 column and eluted
with acetic acid. The fractions were lyophilized to dryness
and reconstituted in 0.03 M P04 buffer, pH 7.4, before assay.
RESULTS
Measurement of immunoreactive somatomedin in
fibroblast medium. Although confluent monolayer
cultures of human fibroblasts were demonstrated to
produce a peptide that reacted in our RIA, the amount
of this material in medium was generally under-
estimated. When 20-120 ,ul of medium that had been
exposed to cells for 72 h were incubated with 1251_
somatomedin-C in immunoassay buffer, the curve of
competition obtained was not parallel to that obtained
using pure standard (Fig. 1). Because the soma-
tomedins have been shown to circulate in plasma
bound to binding proteins, and cultured cells have
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FIGURE 1 Dose-response curve for unextracted, conditioned
medium. Medium that had been exposed to human fibro-
blasts for 24 h was assayed at multiple concentrations for
somatomedin-C (SM-C) content. The results are plotted on a
logit-log scale and the dose response of medium (0) is com-
pared to the dose responses of pure somatomedin-C (0).
somatomedin binding activity, we were concerned that
this lack of parallelism was the result of binding
proteins in the fibroblast culture media. We also ob-
served that when graded quantities of pure soma-
tomedin-C were added to the medium, the recovery
of the added peptide was incomplete (-23%). This
incomplete recovery was not the result of degradation
of somatomedin-C during immunoassay, because in-
cubation of 125I-somatomedin-C with medium for 48 h
(40 or 24°C) resulted in no loss ofbinding when samples
were subsequently exposed to an excess of soma-
tomedin antibody. Several perturbations of medium
were tested to eliminate the effect of these interfering
substances, and to achieve parallelism and full re-
covery. Heating media at 240, 370, or 56°C for variable
periods of time had no effect. Reducing the pH of
medium samples to 3.6 for 30 min and subsequent
neutralization, however, produced dose-response
curves parallel to the pure standard (Fig. 2). 62% ofpure
somatomedin-C that had been added to acidified
media samples was recovered, and there was an eight-
fold enhancement of somatomedin activity over media
which had not been acid treated. In subsequent
studies, therefore, media were subjected routinely to
acid treatment before assay.
Production of immunoreactive somatomedin by
fibroblasts. Confluent cultures of human fibroblasts
were washed three times with serum-free MEM
and exposed to MEM containing 0.1% BSA. No
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FIGURE 3 Production of somatomedin-C by human fibro-
blast cultures. Confluent human fibroblast cultures were
exposed to serum-free MEM containing 0.1% BSA. Media
were removed at the times indicated, and the somatomedin
concentration determined by RIA.
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FIGURE 2 Dose-response curve for acid-treated medium.
Medium (1.0 ml) that had been exposed to human fibro-
blasts for 24 h was acidified by adding 1.0 ml of 2.0 M
acetic acid (final pH 3.6). After 30 min at 37°C, the mixture
was neutralized using 0.015 ml of 0.1 N NaOH. The dose-
response curve obtained using acidified medium (0) is
compared to that obtained using pure somatomedin-C (0).
immunoreactive somatomedin could be detected in
the third wash. Medium samples removed at 24, 48,
and 72 h showed a progressive rise in immunoreactive
somatomedin concentration (Fig. 3). The quantity of
immunoreactive somatomedin present in the media
at 72 h was two times greater than the concentration
present in the MEM-10% FCS in which the cells
originally had been grown and 12 times greater than
the immunoreactive somatomedin content ofthe cellu-
lar cytosol at the start of the incubation.4
Several additional experiments were performed to
exclude the possibility that immunoreactive soma-
tomedin in FCS had been taken up by the cells and
then released. When 525I-somatomedin-C (4 ng/ml of
medium) was incubated with fibroblast cultures for
48 h and the cells were washed 3 times, only 1.3%
of the labeled hormone remained in the cell-associated
fraction. In another experiment, the MEM-0.1% BSA
4The somatomedin concentration in the cytosol was de-
termined as follows: the cells from 12 monolayers were re-
moved by scraping into prechilled 0.05 M phosphate buffer,
pH 7.4, homogenized and centrifuged at 100,00Og for 60 min.
The supematant fraction was assayed for somatomedin-C
concentration. Controls for recovery included addition be-
fore homogenization of m25I-somatomedin-C (20,000 cpm)
and pure unlabeled somatomedin-C (1 ng/ml). Recovery
was >98% by both methods.
was changed at 12-h intervals for 72 h. The sum of the
individual immunoreactive somatomedin concentra-
tions of the six samples was 3.1 times greater than
the immunoreactive somatomedin concentration in
MEM-10% FCS. Additionally, cells incubated in the
presence ofMEM-0.1% BSA containing cyclohexamide
(50 ,UM) exhibited markedly diminished immuno-
reactive somatomedin production (Table I). Finally,
sixth passage cultures were maintained in MEM
containing 10% hypopituitary serum (<2 ng/ml
somatomedin-C) for 3 wk. The monolayers were then
washed extensively and incubated as usual in MEM-
0.1% BSA. After 48 h, the concentration of immuno-
reactive somatomedin was 0.06 U/ml.
TABLE I
Effect of Cyclohexamide on Somatomedin Production
Time of incubation
Test substance 8 24 48
h
Control (no addition) Undetect- 0.04* 0.07
able
Cyclohexamide Undetect- Undetect- Undetect-
able able able
hGH (10 ng/ml) 0.02 0.13 0.22
hGH (10 ng/ml) Undetect- Undetect- Undetect-
+ cyclohexamide able able able
Confluent fibroblast monolayers were washed with serum-
free MEM, then exposed to MEM-0.1% BSA (control) or
MEM-0.1% BSA plus hGH, 10 ng/ml. Additional wells con-
tained either of these media plus cyclohexamide (50 ,um).
At the times indicated, media from quadruplicate plates were
removed and stored for somatomedin determination.
* Somatomedin values are expressed as units per milliliter
per 105 cells.



















Growth hormone stimulation of immunoreactive
somatomedin production. When graded amounts of
hGH were incubated for 24 h with confluent fibro-
blast monolayers containing only MEM-0.1% BSA,
there was a dose-dependent (1-40 ng hGH/ml)
increase in somatomedin production (Fig. 4). These
fibroblasts, therefore, are sensitive to hGH and display
increases in immunoreactive somatomedin production
at concentrations of growth hormone within the range
normally found in human serum.
Other stimuli of immunoreactive somatomedin
production by fibroblasts. In an additional series of
experiments, confluent human fibroblasts were ex-
posed to MEM-0.1% BSA containing either hGH
(10 ng/ml), PDGF (500 ng/ml), or PDGF plus growth
hormone. With these stimuli, cultured fibroblast
media exhibited a progressive increase in immuno-
reactive somatomedin production over time (Fig. 5).
The combination of PDGF and growth hormone was
additive at the concentrations tested. A variety of
other factors had little effect on immunoreactive
somatomedin production (Table II). In addition to
PDGF and hGH, stimulatory effects were noted
when fibroblast growth factor was added, but not by
cortisol, thyroxin, mouse epidermal growth factor, or
porcine insulin. Bovine growth hormone, added over
a concentration range 5-500 ng/ml, showed sig-
nificant stimulation only at the 500 ng/ml concentra-
tion. This result indicates that bovine growth hormone
is -1% as potent as hGH in inducing the formation
of immunoreactive somatomedin in this system.
Biological and physicochemical properties of im-
munoreactive somatomedin produced by fibroblasts.
To determine whether fibroblast-derived somatomedin
can stimulate cell division, conditioned medium was
added to BALB/c 3T3 cell monolayers in the presence
of 5% hypopituitary PPP (<4 ng/ml immunoreactive
somatomedin-C). For comparison, additional mono-
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FIGuRE 4 Effect of hGH on somatomedin-C pri
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FIGURE 5 Effect of hGH and PDGF on SM-C production.
Confluent monolayers were exposed to serum-free MEM
containing no addition (0), 10 ng/ml (A) hGH, 500 ng/ml
PDGF (A), or hGH plus PDGF (0) in 0.1% BSA.
After incubation for 24 h, the media were harvested and
somatomedin-C content was determined. Results are ex-
pressed as units ofsomatomedin-C per milliliter per 105 cells.
somatomedin-C plus 5% hypopituitary PPP. The
addition of 120 Al conditioned MEM resulted in
stimulation of DNA synthesis that was equal to that
produced when hypopituitary PPP plus 7 ng/ml soma-
tomedin-C was added (Table III). A dose response to
conditioned medium was demonstrable over the con-
centration range tested (10-60% vol/vol).
Conditioned medium that had been acidified and
neutralized (see Methods) was tested for its capacity
to compete with 125I-somatomedin-C for binding to
placental membrane receptors. A parallel dose-
response curve was obtained and the somatomedin
concentration by the receptor assay was estimated
to be 12 vs. 9.2 ng/ml by RIA.
On Sephacryl S-200 chromatography, the immuno-
oduction by reactive material in the media migrated in three
distinct peaks (Fig. 6). Approximately 60% of the
units Of activity eluted in the 140,000 mol wt region and -30%
migrated in a region similar to free somatomedin.




Effect of Hormones on Somatomedin Production




hGH (10 ng/ml) 0.17±+ 0.007*
Fibroblast growth factor (10 ng/ml) 0.13±0.008t
Platelet factor (800 ng/ml) 0.19±0.008*
Epidermal growth factor 0.05±0.003
Hydrocortisone (0.17 AM) 0.04±0.007
Hydrocortisone (1.7 ,tM) Undetectable
Thyroxine (0.13 ILM) 0.05±0.006
Porcine insulin (8.0 x 10" M) 0.06±0.007
Quiescent human fibroblast cultures grown to confluency in
MEM-10% FCS (80,000 cells/well) were washed three times
and then exposed to serum-free MEM, containing 0.10% BSA
plus the test mitogen. After incubation for 24 h at 37°C, 0.5 ml of
medium was removed, centrifuged at 1,400g for 20 min, and
the supernatant fluids stored at -20°C. Before assay the
samples were acidified and neutralized (see Methods). The
results are expressed as units of somatomedin-C per milliliter
per 105 cells.
* Significant at P < 0.01.
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Microtest wells containing confluent quiescent BALB/c 3T3
cells (10,000 cells/well) were exposed to PDGF (1.0 gg/well)
in DME for 5 h. These media were then removed, the mono-
layers were washed twice, and serum-free MEM that had
been exposed to human fibroblast cultures for 48 h was added
(in the percentage of the total volume listed) along with
DME containing 5% hypopituitary PPP (total vol = 0.2 ml).
The somatomedin content of the conditioned medium was
0.12 U/ml. This concentration of pure somatomedin-C has
been shown by us and others (39) to stimulate fibroblast
replication. After 48 h of incubation, each well was washed
twice with 70% methanol and DNA synthesis was measured
by autoradiography. 200 nuclei were counted in each well
and each result (the mean of two wells) is expressed as the
percentage of cells labeled. Additional wells received a
known quantity of pure somatomedin-C standard instead of
serum-free medium and the results were determined as
described.
FIGURE 6 Gel filtration chromatography of medium on
Sephacryl S-200. Medium that had been exposed to fibroblast
cultures for 24 h was dialyzed at 40C against 0.005 M phos-
phate buffer for 48 h, pH 7.4, applied to a Sephacryl S200
column in 0.05 M phosphate buffer, pH 7.4, and eluted by
continuous flow. The lower panel shows the elution profile of
fibroblast medium somatomedin. The upper shows the elution
profile of normal human serum on Sephadex G 200.
A minor peak was detectable in the 90-100,000 mol
wt region. Medium that was acidified and neutralized,
then preincubated for 16 h at 4°C with '25I-soma-
tomedin-C (20,000 cpm), and chromatographed on
Sephacryl S-200 showed no activity in the 140,000 mol
wt region. Approximately 60% of the activity now
eluted in the 70 and 35,000 mol wt regions and 40%
in the mol wt region corresponding to free soma-
tomedin. The 1251-somatomedin-C also migrated in the
region corresponding to free somatomedin. Similar
chromatographic results were obtained when medium
was acidified and chromatographed on G-50 Sephadex
at pH 3.6. Under these conditions, -71% of the
immunoreactive material appeared in the void volume,
and 29% chromatographed at Ka, = 0.5, the region
corresponding to free somatomedin (Fig. 7).
DISCUSSION
Observations ofBurk (27), Shodell (15), and Stoker et al.
(28) suggested that certain types of cultured cells
have the capacity to secrete growth factors into serum-





























FIGuRE 7 Gel filtration chromatography of medium on Sephadex G-50. Medium which had
been exposed to fibroblast cultures for 24 h was acidified (pH 3.6) and incubated for 18 h at 40C with
125I-somatomnedin-C (SM-C). This mixture was applied to a Sephadex G-50 column (20
x 1.6 cm) and eluted with acetic acid, pH 3.6. *, ODmo; 3, somatomedin (units per milliliter
x 10-3); O, 1251_SM_C (cpm).
free medium. Dulak and Temin (29) extended these
observations when they isolated and characterized
multiplication-stimulating activity from medium which
had been exposed to buffalo rat liver cells. More
recent studies by Rechler et al. (18) have identified
multiple peptides with mitogenic activity in this
conditioned medium. The physicochemical and
growth-promoting properties of these peptides are
similar to purified somatomedin-C and to multipli-
cation-stimulating activity which had been isolated
from calf serum. More recently, Todaro and Delarco
(30) have shown that SV-40 transformed cells produce
a polypeptide which crossreacts in the multiplication-
stimulating activity-radioreceptor assay. Other im-
portant growth factors such as colony-stimulating
factor (31), macrophage growth factor (32), and nerve
growth factor (33) are produced by a variety ofcultured
cells. Cultured human fibroblasts have also been
reported to produce a small peptide which stimulates
endothelial cell division (34) and a macromolecule
which enhances fibroblast attachment and stimulates
replication in the presence ofserum (35). The chemical
characteristics of these substances and their spectra
of biologic activity have not been defined.
It has generally been assumed that growth factors
such as somatomedin must be transported through
blood to their target tissues to stimulate growth. The
demonstration by others that growth factors are
produced by cultured cells prompted us to question
whether human fibroblasts might produce immuno-
reactive somatomedin that in turn might stimulate
proliferation within the culture. Our results, as well
as those ofWiedman et al. (36), indicate that fibroblasts
are capable of producing a factor(s) that crossreacts
in immunoassays for basic somatomedin. In humans
it is not known if this property is limited to fibroblasts;
however, studies using fetal mouse tissue explants
suggest that it may be a phenomenon common to more
than one cell type. Based on the observations that
cartilage is not sensitive to direct stimulation by
growth hormone (37), it can be assumed that this
tissue and perhaps others require blood-borne soma-
tomedin for growth.
Preliminary studies indicate that a large portion of
the immunoreactivity in cultured fibroblast medium is
in an acid-stable, high molecular weight form. Simi-
larities between this material and somatomedin-C
purified from human plasma are suggested by the
findings that the former (a) reacts with specific soma-
tomedin-C antiserum, (b) crossreacts with soma-
tomedin-C in the placental membrane radioreceptor
assay, and (c) stimulates DNA synthesis in BALB/c
3T3 cells, which require the addition of somatomedin-
C for replication.
Precise measurement of the immunoreactive soma-
tomedin-like material is difficult, probably because
of interference by the somatomedin binding proteins
contained in the culture medium. Acidifying and then
neutralizing media corrected the nonparallelism of
media immunoreactivity, eliminated protein-binding











activity, and significantly enhanced immunoreactivity.
Similar findings have been observed with media taken
from cultured explants of fetal mouse tissues (17);
however, the loss of 125I-somatomedin-C is contrary to
results reported using human serum (38). Since acid
treatment does not result in conversion to a lower
molecular weight form, its enhanced apparent immuno-
reactivity may result from better access of antibody
to previously inaccessible somatomedin. Alternatively,
some of the apparent immunoreactivity in the macro-
molecular fraction after acid treatment could result
from interference of binding proteins in the RIA. This,
however, appears unlikely because we observed
parallelism between pure somatomedin-C and the acid-
treated media and there is no 125I-somatomedin-C
binding on gel chromatography.
The major question concerning growth hormone's
mechanism of action has been whether it stimulates
cell replication directly, or acts through the induction
of an intermediary substance such as somatomedin.
Our results seem to strenghten the possibility of an
indirect action. They demonstrate that the growth
hormone, at concentrations comparable to those in
human serum, stimulates cultured postnatal human
fibroblasts to produce immunoreactive somatomedin.
We have presented evidence recently that supports
the hypothesis that somatomedin mediates the growth-
promoting effects of growth hormone on cultured cells
(39). Specifically, we have observed that when medium
containing hypopituitary PPP and growth hormone is
removed and replenished every 2 h, replication of
fibroblast cultures does not proceed at a normal rate.
Frequent changing of medium containing hypopituitary
PPP and purified somatomedin-C, however, allows
replication to proceed normally. These observations
suggest that somatomedin production is necessary
for normal fibroblast replication and the effect of
growth hormone on fibroblasts is mediated through
somatomedin production.
The potential importance of growth hormone-regu-
lated immunoreactive somatomedin production by
fibroblasts is that it might be the mechanism whereby
growth hormone stimulates generalized cell growth.
In contrast, stimulation of fibroblast immunoreactive
somatomedin production by PDGF represents a non-
growth hormone-dependent mechanism by which
fibroblast replication in culture could be stimulated.
PDGF has been proposed as a growth factor which
stimulates the rapid proliferation of fibroblasts during
wound healing (40). Stimulation of immunoreactive
somatomedin production by PDGF could be one mech-
anism by which these events occur.
The system we have used for assessing immuno-
reactive somatomedin production has a number of
uses. In addition to serving as a tool for the study of
the hormonal control of immunoreactive somatomedin
biosynthesis, it could be useful in assessing non-
hormonal factors that regulate immunoreactive soma-
tomedin production, and as an alternate means for
determining the biological potency of growth hormone
preparations.
There is evidence that fibroblast growth factor stimu-
lates cellular proliferation by a mechanism similar to
PDGF (8). The capacity of a highly purified fibroblast
growth factor preparation to substitute in our system
for partially purified PDGF suggests that a single pep-
tide in the platelet factor preparation may be respon-
sible for stimulation of immunoreactive somatomedin
production. The failure of epidermal growth factor,
thyroxin, and insulin to stimulate immunoreactive
somatomedin production suggests that the process is
specific for certain peptides and implies that epidermal
growth factor and insulin stimulate mitosis through
mechanisms independent of immunoreactive soma-
tomedin production. Our studies indicate that bovine
growth hormone is a weak stimulator of immuno-
reactive somatomedin production. The concentrations
of bovine growth hormone required are comparable
to those necessary to compete with hGH for binding
to receptors in human tissue (41).
The observation that hypopituitary serum is as
potent as normal serum in stimulating fibroblast
replication suggests that immunoreactive somatomedin
production by the fibroblast cultures may be nul-
lifying any differences in the intrinsic mitogenic
capacity of these two types of sera. The findings of
Moses et al. (7), that hypopituitary serum stimulates
DNA synthesis by cultured cells, could be explained
if their hypopituitary test serum contained enough
PDGF to stimulate in vitro production of immuno-
reactive somatomedin that, in turn, stimulated pro-
liferation of their cultured fibroblasts. Alternatively,
other somatomedins that are slightly growth hormone-
dependent and, therefore present in hypopituitary
serum, may stimulate replication in this cell type.
Although immunoreactive somatomedin generally
has been considered to be a blood-borne hormone
with widespread stimulatory effects on cell prolifera-
tion, our findings indicate that fibroblast-derived
somatomedin may regulate proliferation of selected
cell types at or near its site of production. Such local
regulation could provide a mechanism whereby focal
cellular proliferation could be coordinated without
stimulation of adjacent tissues. Such a mechanism
might be an important component of normal physi-
ologic processes such as wound healing, or in disorders
of cellular proliferation such as atherosclerosis.
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